Advertisement

High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity

Published:November 13, 2013DOI:https://doi.org/10.1016/j.radonc.2013.09.025

      Abstract

      Background

      To evaluate early urinary (GU) and gastrointestinal (GI) adverse events (AEs) after two or one fraction of high-dose rate brachytherapy (HDR-BT) in advanced prostate cancer.

      Patients and methods

      165 patients were treated with 2 × 13 Gy (n = 115), or a single dose of 19 Gy (n = 24) or 20 Gy (n = 26) HDR-BT. Early AEs were assessed using the RTOG scoring system and the International Prostate Symptom Score (IPSS).

      Results

      Week-2 prevalence of severe IPSS symptoms was higher after 20 Gy than after 26 or 19 Gy but by 12 weeks all groups were at pre-treatment levels or less. Grade-3 GU toxicity was observed ⩽9% of patients. No Grade 4 GU and no Grade 3 or 4 GI complications were observed. However, there was a significant increase in catheter use in the first 12 weeks after implant after 19 and 20 Gy compared with 2 × 13 Gy.

      Conclusion

      Single dose HDR-BT is feasible with acceptable levels of acute complications; tolerance may have been reached with the single 19 Gy schedule.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ghilezan M.
        • Martinez A.
        • Gustason G.
        • Krauss D.
        • Antonucci J.V.
        • Chen P.
        • et al.
        High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data.
        Int J Radiat Oncol Biol Phys. 2012; 83: 927-932
        • Corner C.
        • Rojas A.M.
        • Bryant L.
        • Ostler P.
        • Hoskin P.
        A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 72: 441-446
        • Demanes D.J.
        • Martinez A.A.
        • Ghilezan M.
        • Hill D.R.
        • Schour L.
        • Brandt D.
        • et al.
        High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2011; 81: 1286-1292
        • Hoskin P.
        • Rojas A.
        • Lowe G.
        • Bryant L.
        • Ostler P.
        • Hughes R.
        • et al.
        High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence.
        Int J Radiat Oncol Biol Phys. 2012; 82: 1376-1384
        • Martinez A.A.
        • Demanes J.
        • Vargas C.
        • Schour L.
        • Ghilezan M.
        • Gustafson G.S.
        High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
        Am J Clin Oncol. 2010; 33: 481-488
        • White E.C.
        • Kamrava M.R.
        • Demarco J.
        • Park S.J.
        • Wang P.C.
        • Kayode O.
        • et al.
        High-dose-rate prostate brachytherapy consistently results in high quality dosimetry.
        Int J Radiat Oncol Biol Phys. 2013; 85: 543-548
        • Yoshioka Y.
        • Konishi K.
        • Sumida I.
        • Takahashi Y.
        • Isohashi F.
        • Ogata T.
        • et al.
        Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions.
        Int J Radiat Oncol Biol Phys. 2011; 80: 469-475
        • Hoskin P.J.
        • Colombo A.
        • Henry A.
        • Niehoff P.
        • Paulsen Hellebust T.
        • Siebert F.A.
        • et al.
        GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update.
        Radiother Oncol. 2013; 197: 325-332
        • Simnor T.
        • Li S.
        • Lowe G.
        • Ostler P.
        • Bryant L.
        • Chapman C.
        • et al.
        Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer.
        Radiother Oncol. 2009; 93: 253-258
        • Barkati M.
        • Williams S.G.
        • Foroudi F.
        • Tai K.H.
        • Chander S.
        • van Dyk S.
        • et al.
        High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial.
        Int J Radiat Oncol Biol Phys. 2012; 82: 1889-1896
        • Ghadjar P.
        • Keller T.
        • Rentsch C.A.
        • Isaak B.
        • Behrensmeier F.
        • Stroux A.
        • et al.
        Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
        Brachytherapy. 2009; 8: 45-51
        • Prada P.J.
        • Jimenez I.
        • Gonzalez-Suarez H.
        • Fernandez J.
        • Cuervo-Arango C.
        • Mendez L.
        High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results.
        Brachytherapy. 2012; 11: 105-110
        • Yoshioka Y.
        • Konishi K.
        • Oh R.J.
        • Sumida I.
        • Yamazaki H.
        • Nakamura S.
        • et al.
        High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer.
        Radiother Oncol. 2006; 80: 62-68
        • Zamboglou N.
        • Tselis N.
        • Baltas D.
        • Buhleier T.
        • Martin T.
        • Milickovic N.
        • et al.
        High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.
        Int J Radiat Oncol Biol Phys. 2012; 85: 672-678
        • Davis B.J.
        • Horwitz E.M.
        • Lee W.R.
        • Crook J.M.
        • Stock R.G.
        • Merrick G.S.
        • et al.
        American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.
        Brachytherapy. 2012; 11: 6-19
        • Salembier C.
        • Lavagnini P.
        • Nickers P.
        • Mangili P.
        • Rijnders A.
        • Polo A.
        • et al.
        Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.
        Radiother Oncol. 2007; 83: 3-10
        • Gomez-Iturriaga Pina A.
        • Crook J.
        • Borg J.
        • Ma C.
        Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) >/=180 Gy.
        Int J Radiat Oncol Biol Phys. 2010; 78: 422-427
        • Kollmeier M.A.
        • Stock R.G.
        • Stone N.
        Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
        Int J Radiat Oncol Biol Phys. 2003; 57: 645-653
        • Stock R.G.
        • Stone N.N.
        • Tabert A.
        • Iannuzzi C.
        • DeWyngaert J.K.
        A dose-response study for I-125 prostate implants.
        Int J Radiat Oncol Biol Phys. 1998; 41: 101-108